Abstract The humoral immune response to SARS‐CoV‐2 results in antibodies against spike (S) and nucleoprotein (N). However, whilst there are widely available neutralization assays for S antibodies, there is no assay for N‐antibody activity. Here, we present a simple in vitro method called EDNA (electroporated‐antibody‐dependent neutralization assay) that provides a quantitative measure of N‐antibody activity in unpurified serum from SARS‐CoV‐2 convalescents. We show that N antibodies neutralize SARS‐CoV‐2 intracellularly and cell‐autonomously but require the cytosolic Fc receptor TRIM21. Using EDNA, we show that low N‐antibody titres can be neutralizing, whilst some convalescents possess serum with high titres but weak activity. N‐antibody and N‐specific T‐cell activity correlates within individuals, suggesting N antibodies may protect against SARS‐CoV‐2 by promoting antigen presentation. This work highlights the potential benefits of N‐based vaccines and provides an in vitro assay to allow the antibodies they induce to be tested. A new in vitro assay, EDNA, measures neutralizing activities of patient antibodies against coronaviral N protein, complementing available methods for evaluating antiviral activities of anti‐spike (S) protein antibodies.
【저자키워드】 antibodies, neutralization, SARS‐CoV‐2, Microbiology, Virology & Host Pathogen Interaction, nucleoprotein, TRIM21, 【초록키워드】 Vaccine, antibody, antiviral activity, SARS‐CoV‐2, Protein, serum, Neutralizing activity, Neutralization assay, Patient, N protein, Neutralizing, humoral immune response, receptor, Antigen presentation, nucleoprotein, convalescent, TRIM21, Quantitative, antiviral activities, measure, titre, neutralizing activities, potential benefits, Coronaviral, neutralize, highlight, PROTECT, tested, provide, potential benefit, induce, individuals, cytosolic, T‐cell, the antibody, 【제목키워드】 antibody, SARS‐CoV‐2, functional,